Drugs / BE-101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06611436 | Dec 2024 → May 2026 | hemophilia B | Be Biopharma | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BE-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06611436 ↗ |
| Route | Intravenous | “a single intravenous (IV) dose of BE-101” NCT06611436 ↗ |